Publications by authors named "Jan Samuelsson"

Claim this Profile
I
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera.
Yan Beauverd, Jean-Christophe Ianotto, Kyaw Htin Thaw, Marta Sobas, Parvis Sadjadian, Jan Samuelsson

Leukemia· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Childbirth rates in women with myeloproliferative neoplasms.
Anna Ravn Landtblom, Therese M-L Andersson, Anna L V Johansson, Frida E Lundberg, Jan Samuelsson

Leukemia· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monocytosis in primary care and risk of haematological malignancies.
Mathilde Egelund Christensen, Volkert Siersma, Margit Kriegbaum, Bent Struer Lind, Jan Samuelsson

Eur J Haematol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival and risk of vascular complications in myelofibrosis-A population-based study from the Swedish MPN group.
Marie Lindgren, Björn Andréasson, Jan Samuelsson, Helna Pettersson, Anneli Enblom-Larsson

Eur J Haematol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms-a nationwide population-based study of 342 pregnancies in Sweden.
Anna Ravn Landtblom, Therese M-L Andersson, Anna L V Johansson, Sophia Brismar Wendel, Frida E Lundberg, Jan Samuelsson

Leukemia· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloproliferative neoplasms - a global view.
Ayalew Tefferi, Jean-Christophe Ianotto, Vikram Mathews, Jan Samuelsson, Natasha Szuber

Br J Haematol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.
Marta Sobas, Jean-Jacques Kiladjian, Yan Beauverd, Natalia Curto-Garcia, Parvis Sadjadian, Jan Samuelsson

Blood Adv· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of infections in patients with myeloproliferative neoplasms-a population-based cohort study of 8363 patients.
Anna Ravn Landtblom, Therese M-L Andersson, Paul W Dickman, Karin E Smedby, Sandra Eloranta, Jan Samuelsson

Leukemia· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry.
Göran Wålinder, Jan Samuelsson, Per Näsman, Markus Hansson, Gunnar Juliusson

Eur J Haematol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up.
Erik Ahlstrand, Jan Samuelsson, Marie Lindgren, Helna Pettersson, Maria Liljeholm

Eur J Haematol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group.
Gunnar Birgegard, Jan Samuelsson, Erik Ahlstrand, Elisabeth Ejerblad, Christian Enevold

Eur J Haematol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.
Anna Ravn Landtblom, Hannah Bower, Therese M-L Andersson, Paul W Dickman, Jan Samuelsson

Leukemia· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms.
Marie Lindgren, Jan Samuelsson, Lars Nilsson, Håvar Knutsen, Waleed Ghanima

Eur J Haematol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thromboembolism prophylaxis in patients with Philadelphia-negative myeloproliferative neoplasms-Clinical practice among Nordic specialists.
Ole Weis Bjerrum, Jan Samuelsson, Waleed Ghanima, Marjut Kauppila, Christen Lykkegaard Andersen

Eur J Haematol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.
Allison H Scotch, Heidi Kosiorek, Robyn Scherber, Amylou C Dueck, Stefanie Slot, Jan Samuelsson

Leuk Res· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry.
Khadija Abdulkarim, Jan Samuelsson, Peter Johansson, Björn Andréasson

Eur J Haematol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
Holly L Geyer, Heidi Kosiorek, Amylou C Dueck, Robyn Scherber, Stefanie Slot, Jan Samuelsson

Haematologica· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
Alberto Alvarez-Larrán, Arturo Pereira, Paola Guglielmelli, Juan Carlos Hernández-Boluda, Eduardo Arellano-Rodrigo, Jan Samuelsson

Haematologica· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.
Holly L Geyer, Bjorn Andreasson, Heidi E Kosiorek, Amylou C Dueck, Robyn M Scherber, Jan Samuelsson

Cancer· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
Holly Geyer, Robyn Scherber, Heidi Kosiorek, Amylou C Dueck, Jean-Jacques Kiladjian, Jan Samuelsson

J Clin Oncol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study.
Malin Hultcrantz, Sally R Wilkes, Sigurdur Y Kristinsson, Therese M-L Andersson, Åsa R Derolf, Jan Samuelsson

J Clin Oncol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival in patients with familial and sporadic myeloproliferative neoplasms.
Malin Hultcrantz, Sigrún H Lund, Ola Landgren, Jan Samuelsson, Lynn R Goldin

Blood· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.
Christen Lykkegaard Andersen, Mads Emil Bjørn, Mary Frances McMullin, Claire Harrison, Jan Samuelsson

Leuk Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.
Holly L Geyer, Robyn M Scherber, Amylou C Dueck, Jean-Jacques Kiladjian, Zhijian Xiao, Jan Samuelsson

Blood· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.
Christen L Andersen, Mary F McMullin, Elisabeth Ejerblad, Sonja Zweegman, Claire Harrison, Jan Samuelsson

Br J Haematol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis